CNS Drugs

, Volume 18, Issue 14, pp 981–988 | Cite as

Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Acute Ischaemic Stroke

Scientific Rationale and Available Evidence
  • Arthur M. Pancioli
  • Thomas G. Brott
Leading Article


Acute ischaemic stroke is the result of an abrupt interruption of focal cerebral blood flow. In the majority of cases, this interruption is caused by an acute thromboembolism. Based on clinical experience in the treatment of acute coronary syndromes, platelet glycoprotein (GP) IIb/IIIa receptor antagonists alone, in combination with reduced doses of thrombolytic agents, or as complementary therapy for short-term mechanical interventions merit consideration as a class of agents with potential use in ischaemic stroke. Research to date and extrapolation from the cardiac literature suggest significant, but as yet unproven, potential for the use of GP IIb/IIIa receptor antagonists in the treatment of acute ischaemic stroke. This potential exists both at the site of the thromboembolic occlusion and at the distal microvascular level. This article reviews the scientific rationale and available evidence for the potential use of platelet GP IIb/IIIa receptor antagonists in acute ischaemic stroke.


Middle Cerebral Artery Occlusion Acute Ischaemic Stroke Abciximab Alteplase Carotid Artery Stenting 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr Pancioli is the principal investigator and Dr Brott is the principal neurologist for the CLEAR (Combined approach to Lysis using Eptifibatide and rt-PA in acute ischemic stroke) trial. The trial is funded by the National Institute of Neurological Disorders and Stroke (1 P50 NS44283-01). The trial medications are provided by the manufacturers at no cost: eptifibatide provided by Millenium Pharmaceuticals Inc., Cambridge (MA), USA; rt-PA provided by Genentech Inc., San Francisco (CA), USA.


  1. 1.
    Zivin JA. Factors determining the therapeutic window for stroke. Neurology 1998; 50(3): 599–603PubMedCrossRefGoogle Scholar
  2. 2.
    Heiss WD, Thiel A, Grond M, et al. Which targets are relevant for therapy of acute ischemic stroke? Stroke 1999; 30(7): 1486–9PubMedCrossRefGoogle Scholar
  3. 3.
    Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. PROlyse in Acute Cerebral Thromboembolism. JAMA 1999; 282(21): 2003–11PubMedCrossRefGoogle Scholar
  4. 4.
    del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. PROlyse in Acute Cerebral Thromboembolism. Stroke 1998; 29(1): 4–11Google Scholar
  5. 5.
    Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989; 91(3): 311–21PubMedCrossRefGoogle Scholar
  6. 6.
    Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993; 14(1): 3–13PubMedGoogle Scholar
  7. 7.
    Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. N Engl J Med 2000 Sep 7; 343(10): 710–22PubMedCrossRefGoogle Scholar
  8. 8.
    Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55(11): 1649–55PubMedCrossRefGoogle Scholar
  9. 9.
    Crouch MA, Nappi JM, Cheang KI. Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother 2003; 37(6): 860–75PubMedCrossRefGoogle Scholar
  10. 10.
    Proimos G. Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors. J Thromb Thrombolysis 2001; 11(2): 99–110PubMedCrossRefGoogle Scholar
  11. 11.
    Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997 Aug 18; 80(4A): 11–20BCrossRefGoogle Scholar
  12. 12.
    Gold HK, Yasuda T, Jang IK, et al. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation 1991; 83(6 Suppl.): IV26–40Google Scholar
  13. 13.
    Yasuda T, Gold HK, Leinbach RC, et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990; 16(7): 1728–35PubMedCrossRefGoogle Scholar
  14. 14.
    Yasuda T, Gold HK, Fallon JT, et al. A canine model of coronary artery thrombosis with superimposed high grade stenosis for the investigation of rethrombosis after thrombolysis. J Am Coll Cardiol 1989; 13(6): 1409–14PubMedCrossRefGoogle Scholar
  15. 15.
    Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99(21): 2720–32PubMedCrossRefGoogle Scholar
  16. 16.
    The Abciximab in Ischemic Stroke Investigators. Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 2000; 31: 601–9CrossRefGoogle Scholar
  17. 17.
    AbESST Investigators. Effects of abciximab for acute ischemic stroke: final results of Abciximab in Emergent Stroke Treatment Trial (AbESTT) [abstract]. Stroke 2003; 34: 253Google Scholar
  18. 18.
    Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000; 36(5): 1489–96PubMedCrossRefGoogle Scholar
  19. 19.
    Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22(2): 381–9PubMedCrossRefGoogle Scholar
  20. 20.
    Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95(4): 846–54PubMedCrossRefGoogle Scholar
  21. 21.
    Topol EJ, Investigators TG. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001; 357: 1905–14PubMedCrossRefGoogle Scholar
  22. 22.
    Krucoff MW, Green CL, Langer A, et al. The Abciximab ST-Recovery on AMI (ASTRONAMI) GUSTO-V substudy: enhanced early speed, stability, quality of reperfusion with anti-platelet augmented thrombolytic therapy for ST-elevation AMI. J Am Coll Cardiol 2002; 39 (5)Suppl. 2: 306CrossRefGoogle Scholar
  23. 23.
    McDonald CT, O’Donnell J, Bemporad J, et al. The clinical utility of intravenous Integrilin combined with intraarterial tissue plasminogen activator in acute ischemic stroke: the MGH experience [abstract]. Stroke 2002; 96: 359AGoogle Scholar
  24. 24.
    Seitz RJ, Hamzavi M, Junghans U, et al. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke. Stroke 2003; 34: 1932–5PubMedCrossRefGoogle Scholar
  25. 25.
    Morris DC, Silver B, Mitsias P, etal. Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab. Acad Emerg Med 2003; 10(12): 1396–9PubMedCrossRefGoogle Scholar
  26. 26.
    Gawaz M, Neumann FJ, Ott I, et al. Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart 1996; 76(2): 166–72PubMedCrossRefGoogle Scholar
  27. 27.
    Gawaz M, Neumann FJ, Ott I, et al. Platelet activation and coronary stent implantation: effect of antithrombotic therapy. Circulation 1996; 94(3): 279–85PubMedCrossRefGoogle Scholar
  28. 28.
    Gawaz M, Ruf A, Neumann FJ, et al. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement. Thromb Haemost 1998; 80(6): 994–1001PubMedGoogle Scholar
  29. 29.
    The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352: 87–92Google Scholar
  30. 30.
    Kereiakes DJ, Lincoff AM, Miller DP, et al. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Circulation 1998; 97(9): 857–64Google Scholar
  31. 31.
    Yadav JS, Roubin GS, Iyer S, et al. Elective stenting of the extracranial carotid arteries. Circulation 1997; 95(2): 376–81PubMedCrossRefGoogle Scholar
  32. 32.
    Yadav JS, Roubin GS, King P, et al. Angioplasty and stenting for restenosis after carotid endarterectomy: initial experience. Stroke 1996; 27(11): 2075–9PubMedCrossRefGoogle Scholar
  33. 33.
    Wholey MH, Wholey M, Bergeron P, et al. Current global status of carotid artery stent placement. Cathet Cardiovasc Diagn 1998; 44(1): 1–6PubMedCrossRefGoogle Scholar
  34. 34.
    Cecena FA, Hoelzinger DH, Miller JA, et al. The platelet IIb/IIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions. J Interv Cardiol 1999; 12: 355–62CrossRefGoogle Scholar
  35. 35.
    Ho DS, Wang Y, Chui M, et al. Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty. Cerebrovasc Dis 2001; 11(4): 300–4PubMedCrossRefGoogle Scholar
  36. 36.
    Kapadia SR, Bajzer CT, Ziada KM, et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 2001; 32(10): 2328–32PubMedCrossRefGoogle Scholar
  37. 37.
    Qureshi AI, Siddiqui AM, Hanel RA, et al. Safety of high-dose intravenous Eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry. Neuro-surgery 2004; 54(2): 307–17Google Scholar
  38. 38.
    Wholey MH, Eles G, Toursakissian B, et al. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 2003; 10(1): 33–41PubMedCrossRefGoogle Scholar
  39. 39.
    Verheugt FW, Meijer A, Lagrand WK, et al. Reocclusion: the flip side of coronary thrombolysis. J Am Coll Cardiol 1996; 27(4): 766–73PubMedCrossRefGoogle Scholar
  40. 40.
    Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349(8): 733–42PubMedCrossRefGoogle Scholar
  41. 41.
    Grotta JC, Welch KM, Fagan SC, et al. Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke 2001; 32(3): 661–8PubMedCrossRefGoogle Scholar
  42. 42.
    Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002; 59(6): 862–7PubMedCrossRefGoogle Scholar
  43. 43.
    Heo JH, Lee KY, Kim SH, et al. Immediate reocclusion following a successful thrombolysis in acute stroke: a pilot study. Neurology 2003; 60(10): 1684–7PubMedCrossRefGoogle Scholar
  44. 44.
    Junghans U, Seitz RJ, Wittsack HJ, et al. Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/ IIIa inhibitor: report of four cases. Radiology 2001; 221(3): 795–801PubMedCrossRefGoogle Scholar
  45. 45.
    Eckert B, Koch C, Thomalla G, et al. Acute basilar artery occlusion treated with combined intravenous Abciximab and intra-arterial tissue plasminogen activator: report of 3 cases. Stroke 2002; 33(5): 1424–7PubMedCrossRefGoogle Scholar
  46. 46.
    Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101(5): 570–80PubMedCrossRefGoogle Scholar
  47. 47.
    Choudhri TF, Hoh BL, Zerwes HG, et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 1998; 102(7): 1301–10PubMedCrossRefGoogle Scholar
  48. 48.
    Garcia JH, Liu KF, Yoshida Y, et al. Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994; 144(1); 188–99PubMedGoogle Scholar
  49. 49.
    Zhang ZG, Zhang L, Tsang W, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 2001; 912(2): 181–94PubMedCrossRefGoogle Scholar
  50. 50.
    Abumiya T, Fitridge R, Mazur C, et al. Integrin alpha (IIb)beta (3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 2000; 31(6): 1402–9PubMedCrossRefGoogle Scholar
  51. 51.
    Okada Y, Copeland BR, Mori E, et al. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion. Stroke 1994; 25(1): 202–11PubMedCrossRefGoogle Scholar
  52. 52.
    Okada Y, Copeland BR, Fitridge R, et al. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke 1994; 25(9): 1847–53PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Emergency MedicineUniversity of CincinnatiCincinnatiUSA
  2. 2.Department of NeurologyMayo ClinicJacksonvilleUSA

Personalised recommendations